<?xml version="1.0" encoding="UTF-8"?>
<p id="p0195">However, concerns are raised about a rush to deploy a COVID-19 vaccine. Applying ‘Quick fix’ and ‘short cuts’ can lead to errors with disastrous consequences (
 <xref rid="bib84" ref-type="bibr">84</xref>). What regulators have to worry about is the atmosphere of hype about the COVID-19 vaccine? Public claims about breakthrough research based on poorly conducted studies or data collected through fraud is a real possibility. All data which form the basis of any findings need to be scrutinized and should be confirmed by other investigators. Relaxion on regulatory principles based on political pressure and goodwill needs to be resisted and one needs to protect the interests of volunteers who are a part of such experiments (
 <xref rid="bib85" ref-type="bibr">85</xref>). Lastly, vaccine development is a risky process, and one critical issue in the COVID-19 vaccine would-be the occurrence of ‘Antibody-Dependent Enhancement (ADE)’ which may be disastrous for those receiving the vaccine (
 <xref rid="bib49" ref-type="bibr">49</xref>, 
 <xref rid="bib50" ref-type="bibr">50</xref>). Regulators have to take all precautions to discourage candidate vaccines which may show such a phenomenon.
</p>
